We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Monte Rosa Therapeutics Inc (GLUE) USD0.0001

Sell:$9.51 Buy:$9.62 Change: $0.50 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.50 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.50 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company. It is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

Contact details

645 Summer Street, Suite 102
United States
+1 (617) 9492643

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$477.88 million
Shares in issue:
46.67 million
United States
US dollar

Key personnel

  • Markus Warmuth
    President, Chief Executive Officer, Director
  • Ajim Tamboli
    Chief Financial Officer
  • Sharon Townson
    Chief Technology Officer
  • Owen Wallace
    Chief Scientific Officer
  • Philip Nickson
    General Counsel
  • John Castle
    Chief Data Scientist
  • Filip Janku
    Chief Medical Officer
  • Jullian Jones
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.